UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

(Shutterstock)

More from Innovation

More from Leadership